NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

侵入性真菌感染疾病(IFI)的全球市場:疾病類型、產品線治療藥、各地區

Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)

出版商 Azoth Analytics 商品編碼 923534
出版日期 內容資訊 英文 225 Pages
訂單完成後即時交付
價格
侵入性真菌感染疾病(IFI)的全球市場:疾病類型、產品線治療藥、各地區 Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)
出版日期: 2020年01月31日內容資訊: 英文 225 Pages
簡介

全球侵入性真菌感染疾病(IFI)市場在2018年估算為成為61億350萬美元規模的市場。HIV和AIDS的患病者增加,產品線醫藥品的藥物研發、開發,接受化療的患者劇增,廣域抗生素的使用增加等促進這個市場成長。

本報告提供全球侵入性真菌感染疾病(IFI)市場調查,市場概要,各疾病、各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查方法與摘要整理

  • 調查方法
  • 摘要整理

第2章 策略性的推薦事項

第3章 產品預測

第4章 全球侵入性真菌感染疾病(IFI)市場:市場規模與預測

  • 市場規模:以金額為準(成果值、預測值)

第5章 全球侵入性真菌感染疾病(IFI)市場:各疾病

  • 競爭方案:各疾病
  • 念珠菌血症、侵入性念珠菌症
  • 腹腔內念珠菌症(念珠菌腹膜炎)
  • 隱球菌腦膜炎
  • 組織漿菌症的普及
  • 急性肺組織漿菌症
  • 侵入性麴菌症
  • 浸潤性鼻竇炎
  • 白黴菌症
  • 肺囊蟲肺炎
  • 其他

第6章 全球侵入性真菌感染疾病(IFI)市場:各地區

  • 競爭模式:各地區

第7章 北美的侵入性真菌感染疾病(IFI)市場

  • 北美的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 北美的侵入性真菌感染疾病(IFI)市場:主要企業
  • 市場區隔:各疾病
  • 市場分析:各國
  • 市場機會
  • 競爭模式:各國
  • 美國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 美國的侵入性真菌感染疾病(IFI)市場:各疾病
  • 加拿大的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 加拿大的侵入性真菌感染疾病(IFI)市場:各疾病

第8章 歐洲的侵入性真菌感染疾病(IFI)市場

  • 北美的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 北美的侵入性真菌感染疾病(IFI)市場:主要企業
  • 市場區隔:各疾病
  • 市場分析:各國
  • 市場機會
  • 競爭模式:各國
  • 德國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 德國的侵入性真菌感染疾病(IFI)市場:各疾病
  • 英國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 英國的侵入性真菌感染疾病(IFI)市場:各疾病
  • 西班牙的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 西班牙的侵入性真菌感染疾病(IFI)市場:各疾病
  • 其他國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 其他國的侵入性真菌感染疾病(IFI)市場:各疾病

第9章 亞太地區的侵入性真菌感染疾病(IFI)市場

  • 亞太地區的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 亞太地區的侵入性真菌感染疾病(IFI)市場:主要企業
  • 市場區隔:各疾病
  • 市場分析:各國
  • 市場機會
  • 競爭模式:各國
  • 中國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 中國的侵入性真菌感染疾病(IFI)市場:各疾病
  • 韓國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 韓國的侵入性真菌感染疾病(IFI)市場:各疾病
  • 日本的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 日本的侵入性真菌感染疾病(IFI)市場:各疾病
  • 印度的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 印度的侵入性真菌感染疾病(IFI)市場:各疾病
  • 其他國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 其他國的侵入性真菌感染疾病(IFI)市場:各疾病

第10章 其他地區的侵入性真菌感染疾病(IFI)市場

  • 其他地區的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 其他地區的侵入性真菌感染疾病(IFI)市場:主要企業
  • 市場區隔:各疾病
  • 市場分析:各國
  • 市場機會
  • 競爭模式:各國
  • 巴西的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 巴西的侵入性真菌感染疾病(IFI)市場:各疾病
  • 埃及侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 埃及侵入性真菌感染疾病(IFI)市場:各疾病
  • 其他國的侵入性真菌感染疾病(IFI)市場:以金額為準(成果值、預測值)
  • 其他國的侵入性真菌感染疾病(IFI)市場:各疾病

第11章 市場動態

  • 成長要素
  • 阻礙因素
  • 市場趨勢

第12章 產品線醫藥品分析

第13章 市場魅力分析

  • 市場魅力分析:各疾病
  • 市場魅力分析:各地區

第14章 競爭情形

  • 市場佔有率分析
  • SWOT分析
  • 波特的五力分析

第15章 企業簡介

  • Cidara Therapeutics
  • Basilea Pharmaceutica
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • Abbott
  • Merck & Co
  • Astellas Pharma Inc.
  • F2G- the Rare Fungal Disease Company
  • Scynexis Inc.
目錄

Executive Summary:

Global Invasive Fungal Infection Market was valued at USD 6103.5 Million in the year 2018. The rise in population suffering from HIV/AIDS, discovery and advancement of pipeline drugs and facilities provided by hospitals in intensive care units for those who have undergone surgery, surge in chemotherapy and increase in use of broad spectrum antibiotics and global economic growth is going to accelerate the invasive fungal infection market. Introduction of advanced medicines has already proven to be constructive as it directly improves the health of immuno-compromised patient and enhances the life expectancy of a patient.

The Invasive Fungal Infection market has been estimated to witness growth in future primarily because of surging demand for low-cost pipeline products and increase in use of broad-spectrum antibiotics which makes fungi resistant to various medicines and to opt for the low-cost medicines whose effect can last longer than the traditional medicines.

A number of companies are offering variety of antibiotics which have decreased the resistance of several medicines, thus increasing the incidence of invasive fungal infection. In addition, rising investment by major leading Invasive Antifungal manufacturers in various regions with demand for effective and low cost product and focus of government on educating people about the care taken during the stay in ICU after undergoing solid organ transplantation with various government powered awareness programs that are being run with an aim to eradicate diseases, has been anticipated to spur the market growth during the forecast period.

Scope of the Report:

  • There report analyzes the Global Invasive Fungal Infection Market By Diseases (Candidemia and invasive Candidiasis, Intra-abdominal candidiasis (Candida Peritonitis), Cryptococcal Meningitis, Histoplasmosis Disseminated, Histoplasmosis Acute Pulmonary, Invasive aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others).
  • The Global Invasive Fungal Infection Market has been analysed By Region (North America, Europe, Asia Pacific, ROW) and By Country (United States, Canada, Germany, France, United Kingdom, Spain, China, South Korea, Japan, India).
  • The key insights of the report have been presented through the frameworks of SWOT, Porter and Market Attractiveness charts. Market Attractiveness charts have been presented by diseases and by region. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report provides a detailed pipeline analysis of drugs being developed to cure the problem of Invasive Fungal Infection.
  • The report tracks competitive developments,market share analysis, strategies and new product development. The companies analysed in the report include Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G - The Rare Fungal Disease Company, Scynexis Inc
  • The report presents the analysis of Global Invasive Fungal Infection Market for the historical period of 2014-2018 and the forecast period of 2019-2024.

Key Target Audience:

  • Pharmaceutical Companies
  • Consulting and Advisory Firms
  • Medical Practitioners
  • Regulatory Authorities

Table of Contents

1. Report scope & Methodology

  • 1.1 Scope of the Report
  • 1.2 Research Methodology
  • 1.3 Executive Summary

2. Strategic Recommendations

  • 2.1 Both Healthcare Providers and Public Health Agencies to Improve Diagnostics
  • 2.2 Escalate the awareness among the population of APAC region

3. Global Invasive Fungal Infection Product Outlook

4. Global Invasive Fungal Infection Market: Sizing, Growth, Forecast

  • 4.1 Market Size, By Value, Year 2014-2024

5. Global Invasive Fungal Infection Market Segmentation By Diseases

  • 5.1 Competitive Scenario of Global Invasive Fungal Infection Market: By Diseases
  • 5.2 Candidaemia and invasive candiasis - Market Size and Forecast (2019-2024)
  • 5.3 Intra-abdominal Candiasis (Candida Peritonitis) - Market Size and Forecast (2019-2024)
  • 5.4 Cryptococcal Meningitis - Market Size and Forecast (2019-2024)
  • 5.5 Histoplasmosis Disseminated- Market Size and Forecast (2019-2024)
  • 5.6 Histoplasmosis acute pulmonary - Market Size and Forecast (2019-2024)
  • 5.7 Invasive Aspergillosis - Market Size and Forecast (2019-2024)
  • 5.8 Invasive Rhinosinusitis - Market Size and Forecast (2019-2024)
  • 5.9 Mucormycosis - Market Size and Forecast (2019-2024)
  • 5.10 Pneumocystis Pneumonia - Market Size and Forecast (2019-2024)
  • 5.11 Others - Market Size and Forecast (2019-2024)

6. Global Invasive Fungal Infection Market: Regional Analysis

  • 6.1 Competitive Scenario of Global Invasive Fungal Infection: By Region

7. North America Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)

  • 7.1 North America Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 7.2 North America Invasive Fungal Infection Market - Prominent Companies
  • 7.3 Market Segmentation By Product Type- (Diseases)
  • 7.4 Market Segmentation By Diseases (Candidemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
  • 7.5 North America Invasive Fungal Infection Market: Country Analysis
  • 7.6 Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
  • 7.7 Competitive Scenario of North America Invasive Fungal Infection: By Country
  • 7.8 United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • 7.9 United States Invasive Fungal Infection Market Segmentation- By Diseases
  • 7.10 Canada Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 7.11 Canada Invasive Fungal Infection Market Segmentation- By Diseases

8. Europe Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)

  • 8.1 Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value

(Year-2024)

  • 8.2 Competitive Scenario of Europe Invasive Fungal Infection: By Country
  • 8.3 Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.4 Europe Invasive Fungal Infection Market - Prominent Companies
  • 8.5 Market Segmentation By Diseases- (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
  • 8.6 Europe Invasive Fungal Infection Market: Country Analysis
  • 8.7 Germany Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.8 Germany Invasive Fungal Infection Market Segmentation- By Diseases
  • 8.9 France Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.10 France Invasive Fungal Infection Market Segmentation- By Diseases
  • 8.11 United Kingdom Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.12 United Kingdom Invasive Fungal Infection Market Segmentation- By Diseases
  • 8.13 Spain Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.14 Spain Invasive Fungal Infection Market Segmentation- By Diseases
  • 8.15 Rest of Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 8.16 Rest of Europe Invasive Fungal Infection Market Segmentation- By Product Type, End User

9. Asia Pacific Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)

  • 9.1 Market Opportunity Chart of Asia Pacific Invasive Fungal Infection Market - By Country, By Value

(Year-2024)

  • 9.2 Competitive Scenario of Asia Pacific Invasive Fungal Infection: By Country
  • 9.3 Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.4 Asia Pacific Invasive Fungal Infection Market - Prominent Companies
  • 9.5 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
  • 9.6 Asia Pacific Invasive Fungal Infection Market: Country Analysis
  • 9.7 China Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.8 China Invasive Fungal Infection Market Segmentation- By Diseases
  • 9.9 South Korea Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.10 South Korea Invasive Fungal Infection Market Segmentation- By Diseases
  • 9.11 Japan Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.12 Japan Invasive Fungal Infection Market Segmentation- By Diseases
  • 9.13 India Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.14 India Invasive Fungal Infection Market Segmentation- By Diseases
  • 9.15 Rest of Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 9.16 Rest of Asia Pacific Invasive Fungal Infection Market Segmentation- By Diseases

10. Rest of the World Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)

  • 10.1 Market Opportunity Chart of Rest of the World Invasive Fungal Infection Market - By Country, By Value

(Year-2024)

  • 10.2 Competitive Scenario of Rest of the World Invasive Fungal Infection: By Country
  • 10.3 Rest of the World Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 10.4 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
  • 10.5 Rest of the World Invasive Fungal Infection Market: Country Analysis
  • 10.6 Brazil Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 10.7 Brazil Invasive Fungal Infection Market Segmentation- By Diseases
  • 10.8 Egypt Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 10.9 Egypt Invasive Fungal Infection Market Segmentation- By Diseases
  • 10.10 Rest of the Countries Invasive Fungal Infection Market: Size and Forecast (2019-2024)
  • 10.11 Rest of the Countries Invasive Fungal Infection Market Segmentation- By Diseases

11. Global Invasive Fungal Infection Market Dynamics

  • 11.1 Global Invasive Fungal Infection Market Drivers
  • 11.2 Global Invasive Fungal Infection Market Restraints
  • 11.3 Global Invasive Fungal Infection Market Trends

12. Pipeline Drugs Analysis - Invasive Fungal Infection

13. Market Attractiveness and Strategic Analysis

    • 13.1.1 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases(Year 2024)
    • 13.1.2 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region (Year 2024)

14. Competitive Landscape

  • 14.1 Market Share Analysis
  • 14.2 SWOT Analysis
  • 14.3 Porter's Five Force Analysis

15. Company Analysis (Business Description, Financial Analysis, Business Strategy)

  • 15.1 Cidara Therapeutics
  • 15.2 Basilea Pharmaceutica
  • 15.3 Pfizer
  • 15.4 GlaxoSmithKline
  • 15.5 Bayer AG
  • 15.6 Abbott
  • 15.7 Merck & Co
  • 15.8 Astellas Pharma Inc.
  • 15.9 F2G- the Rare Fungal Disease Company
  • 15.10 Scynexis Inc.

List of Figures

  • Figure 1: Global Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 2: Global Prevalence of HIV, (%), 2013-2017
  • Figure 3: Global Deaths by HIV, (%), 2013-2017
  • Figure 4: Global Prevalence of Neoplasms (%), 2014-2016
  • Figure 5: Global Prevalence of Tuberculosis (%), 2015-2017
  • Figure 6: Competitive Scenario of Global Fungal Infection Market- BY Diseases
  • Figure 7: Global Invasive Fungal Infection Market- By Candidemia and invasive candiasis, By Value (USD Million), 2014-2024
  • Figure 8: Global Invasive Fungal Infection Market- By Intra-abdominal Candiasis (Candida Peritonitis), By Value (USD Million), 2014-2024
  • Figure 9: Global Invasive Fungal Infection Market- By Cryptococcal Meningitis , By Value (USD Million), 2014-2024
  • Figure 10: Global Invasive Fungal Infection Market- By Histoplasmosis Disseminated, By Value (USD Million), 2014-2024
  • Figure 11: Global Invasive Fungal Infection Market- By Histoplasmosis acute pulmonary, By Value (USD Million), 2014-2024
  • Figure 12: Global Invasive Fungal Infection Market- By Invasive Aspergillosis, By Value (USD Million), 2014-2024
  • Figure 13: Global Invasive Fungal Infection Market- By Invasive Rhinosinusitis, By Value (USD Million), 2014-2024
  • Figure 14: Global Invasive Fungal Infection Market- By Mucormycosis, By Value (USD Million), 2014-2024
  • Figure 15: Global Invasive Fungal Infection Market- By Pneumocystis Pneumonia, By Value (USD Million), 2014-2024
  • Figure 16: Global Invasive Fungal Infection Market- By Others, By Value (USD Million), 2014-2024
  • Figure 17: Competitive Scenario of Global Invasive Fungal Infection- By Region
  • Figure 18: North America Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 19: North America Prevalence of HIV, (%), 2013-2017
  • Figure 20: North America Deaths by HIV, (%), 2013-2017
  • Figure 21: North America Prevalence of Neoplasms (%), 2013-2017
  • Figure 22: North America Prevalence of Tuberculosis (%), 2012-2017
  • Figure 23: North America Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 24: North America Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 25: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
  • Figure 26: Competitive Scenario of North America Invasive Fungal Infection- By Country
  • Figure 27: United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 28: US Prevalence of HIV, (%), 2013-2017
  • Figure 29: US Deaths by HIV, (%), 2013-2017
  • Figure 30: US Prevalence of Neoplasms (%), 2014-2016
  • Figure 31: US Prevalence of Tuberculosis (%), 2012-2017
  • Figure 32: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 33: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 34: Canada Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 35: Canada Prevalence of HIV, (%), 2013-2017
  • Figure 36: Canada Deaths by HIV, (%), 2013-2017
  • Figure 37: Canada Prevalence of Neoplasms (%), 2014-2016
  • Figure 38: Canada Prevalence of Tuberculosis (%), 2012-2017)
  • Figure 39: Canada Invasive Fungal Infection Market- By Diseases(USD Million), 2014-2024
  • Figure 40: Canada Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 41: Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value (Year 2024)
  • Figure 42: Competitive Scenario of Europe Invasive Fungal Infection - By Country
  • Figure 43: Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 44: Europe Prevalence of HIV, (%), 2013-2017
  • Figure 45: Europe Deaths by HIV, (%), 2013-2017
  • Figure 46: Europe Prevalence of Neoplasms (%), 2013-2017
  • Figure 47: Europe Prevalence of Tuberculosis (%), 2012-2017
  • Figure 48: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 49: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 50: Germany Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 51: Germany Prevalence of HIV, (%), 2013-2017
  • Figure 52: Germany Deaths by HIV, (%), 2013-2017)
  • Figure 53: Germany Prevalence of Neoplasms (%), 2013-2017
  • Figure 54: Germany Prevalence of Tuberculosis (%), 2012-2017
  • Figure 55: Germany Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 56: Germany Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 57: France Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 58: France Prevalence of HIV, (%), 2013-2017
  • Figure 59: France Deaths by HIV, (%), 2013-2017
  • Figure 60: France Prevalence of Neoplasms (%), 2013-2017
  • Figure 61: France Prevalence of Tuberculosis (%), 2012-2017
  • Figure 62: France Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 63: France Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 64: United Kingdom Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 65: UK Prevalence of HIV, (%), 2013-2017
  • Figure 66: UK Deaths by HIV, (%), 2013-2017
  • Figure 67: UK Prevalence of Neoplasms (%), 2013-2017
  • Figure 68: UK Prevalence of Tuberculosis (%), 2012-2017
  • Figure 69: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 70: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 71: Spain Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 72: Spain Prevalence of HIV, (%), 2013-2017
  • Figure 73: Spain Deaths by HIV, (%), 2013-2017
  • Figure 74: Spain Prevalence of Neoplasms (%), 2013-2017
  • Figure 75: Spain Prevalence of Tuberculosis (%), 2012-2017
  • Figure 76: Spain Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 77: Spain Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 78: Rest of Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 79: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 80: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 81: Market Opportunity Chart of APAC Invasive Fungal Infection Market - By Country, By Value
  • Figure 82: Competitive Scenario of APAC Invasive Fungal Infection - By Country
  • Figure 83: APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 84: Asia Prevalence of HIV, (%), 2013-2017
  • Figure 85: Asia Deaths by HIV, (%), 2013-2017
  • Figure 86: Asia Prevalence of Neoplasms (%), 2013-2017
  • Figure 87: Asia Prevalence of Tuberculosis (%), 2012-2017
  • Figure 88: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 89: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 90: China Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 91: China Prevalence of HIV, (%), 2013-2017
  • Figure 92: China Deaths by HIV, (%), 2013-2017
  • Figure 93: China Prevalence of Neoplasms (%), 2013-2017
  • Figure 94: China Prevalence of Tuberculosis (%), 2012-2017
  • Figure 95: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 96: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
  • Figure 97: South Korea Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 98: South Korea Prevalence of HIV, (%), 2013-2017
  • Figure 99: South Korea Deaths by HIV, (%), 2013-2017
  • Figure 100: South Korea Prevalence of Neoplasms (%), 2013-2017
  • Figure 101: South Korea Prevalence of Tuberculosis (%), 2012-2017
  • Figure 102: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 103: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 104: Japan Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 105: Japan Prevalence of HIV, (%), 2013-2017
  • Figure 106: Japan Incidence of HIV, (%), 2013-2017
  • Figure 107: Japan Prevalence of Neoplasms (%), 2013-2017
  • Figure 108: Japan Prevalence of Tuberculosis (%), 2012-2017
  • Figure 109: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 110: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 111: India Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 112: India Prevalence of HIV, (%), 2013-2017
  • Figure 113: India Incidence of HIV, (%), 2013-2017
  • Figure 114: India Prevalence of Neoplasms (%), 2013-2017
  • Figure 115: India Prevalence of Tuberculosis (%), 2012-2017
  • Figure 116: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 117: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 118: Rest of APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 119: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 120: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 121: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year 2024)
  • Figure 122: Competitive Scenario of Rest of the World Invasive Fungal Infection - By Country
  • Figure 123: Rest of the World Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 124: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 125: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 126: Brazil Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 127: Brazil Prevalence of HIV, (%), 2013-2017
  • Figure 128: Brazil deaths of HIV, (%), 2013-2017
  • Figure 129: Brazil Prevalence of Neoplasms (%), 2013-2017
  • Figure 130: Brazil Prevalence of Tuberculosis (%), 2012-2017
  • Figure 131: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 132: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 133: Egypt Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 134: Egypt Prevalence of HIV, (%), 2013-2017
  • Figure 135: Egypt Incidence of HIV, (%), 2013-2017
  • Figure 136: Egypt Prevalence of Neoplasms (%), 2013-2017
  • Figure 137: Egypt Prevalence of Tuberculosis (%), 2012-2017
  • Figure 138: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 139: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 140: Rest of the Countries Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
  • Figure 141: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 142: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
  • Figure 143: Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases (Year-2024)
  • Figure 144: Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region, By Value, (Year-204)
  • Figure 145: Competitive Positions of Invasive Fungal Infection Companies (2018)
  • Figure 146: Cidara Therapeutics, Research and Development 2016-2018 (In USD Million)
  • Figure 147: Cidara Therapeutics, Research and Development By Product Category, 2018 (In %)
  • Figure 148: Basilea Revenue, 2014-2018 (In USD Billion)
  • Figure 149: Basilea Revenue, By Region, 2017 (In %)
  • Figure 150: Basilea Revenue, By Region, 2018 (In %)
  • Figure 151: Pfizer Revenue, 2014 - 2018 (In USD Billion)
  • Figure 152: Pfizer Sales Revenue, By Region, 2017 (In %)
  • Figure 153: Pfizer Sales Revenue, By Region, 2018 (In %)
  • Figure 154: Pfizer Revenue, By Business Segment, 2017, 2018 (In USD Million)
  • Figure 155: Pfizer Revenue, By IH Segment, By Region 2018 (In %)
  • Figure 156: Pfizer Revenue, By EH Segment, By Region 2018 (In %)
  • Figure 157: GSK, Turnover, 2014 - 2018 (In USD Billion)
  • Figure 158: GSK, Turnover, By Segments, 2017 (In %)
  • Figure 159: GSK, Turnover, By Segments, 2018 (In %)
  • Figure 160: GSK, Turnover, By Geographic Region, 2017 (In %)
  • Figure 161: GSK, Turnover, By Geographic Region, 2018 (In %)
  • Figure 162: Bayer AG, Sales Revenue, 2014 - 2018 (In USD Million)
  • Figure 163: Bayer AG, Net Sales Revenue, By Region, 2017 (In %)
  • Figure 164: Bayer AG, Net Sales Revenue, By Region, 2018 (In %)
  • Figure 165: Abbott Net Income, 2014 - 2018 (In USD Million)
  • Figure 166: Abbott Sales Revenue, By Business Segment, 2017 (In %)
  • Figure 167: Abbott Sales Revenue, By Business Segment, 2018 (In %)
  • Figure 168: Abbott Sales, By Geographic Region, 2017 (In %)
  • Figure 169: Abbott Sales, By Geographic Region, 2018 (In %)
  • Figure 170: Merck & Co, Sales, 2014 - 2018 (In USD Million)
  • Figure 171: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2017 (In %)
  • Figure 172: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2018 (In %)
  • Figure 173: Merck & Co, Sales, By Geographic Region, 2017 (In %)
  • Figure 174: Merck & Co, Sales, By Geographic Region, 2018 (In %)
  • Figure 174: Astellas Pharma Inc., Sales, 2014 - 2018 (In USD Billion)
  • Figure 176: Astellas Pharma Inc., Sales Revenue, By Product, 2018 (In USD Billion)
  • Figure 177: Astellas Pharma Inc., Sales Revenue, By Product, 2019 (In USD Billion)
  • Figure 178: Astellas Pharma Inc. , Sales, By Geographic Region, 2017 (In %)
  • Figure 179: Astellas Pharma Inc. , Sales, By Geographic Region, 2018 (In %)
  • Figure 180: SCYNEXIS Inc., Revenue, 2014 - 2018 (In USD Thousands)

List of Tables

  • Table A Prominent Invasive Fungal Infection Companies Operated in North America Market
  • Table B Prominent Invasive Fungal Infection Companies Operated in Europe Market
  • Table C Prominent Invasive Fungal Infection Companies Operated in APAC Market